Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
MBRXMoleculin(MBRX) Prnewswire·2024-09-23 20:00

Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung CancerTreatment with Annamycin results in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung cancer modelsAnnamycin continues to be 100% non-cardiotoxicHOUSTON, Sept. 23, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candid ...